AUS
NZ
UK
CA
USA
IND
Highlights
- Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years post-vaccination.
- Analysts at Jefferies revised their price target for Novavax from $31 to $25 amid increased uncertainty about the trial timeline.
- Despite the setback, analysts remain optimistic about Novavax’s existing products, particularly its COVID-19 vaccine.
Novavax, Inc. has experienced a significant decline in its stock price after the company announced a clinical hold on its CIC flu combination vaccine program due to a serious adverse event (SAE) reported in a Phase 2 trial participant.
The adverse event of motor neuropathy was reported in September 2024, affecting a participant who had received the vaccine in January 2023. This incident has raised concerns within the biotech community, as Novavax has historically maintained a clean safety record for its vaccine candidates. The unexpected nature of the SAE has caught the attention of analysts and investors alike, leading to a sharp drop in Novavax’s stock.
In a recent communication, analysts from Jefferies expressed surprise at the clinical hold, highlighting the previously robust safety profile of Novavax’s products. The firm noted that Novavax is expected to receive an official letter from the U.S. Food and Drug Administration (FDA) within the next 30 days, detailing the specifics of the hold. In the meantime, Novavax has committed to addressing the situation as quickly as possible, collaborating closely with the FDA to ascertain whether a causal link exists between the vaccine and the reported adverse event.
Following the news, Novavax’s stock price fell nearly 20%, trading at approximately $10.10 on Wednesday afternoon. This decline reflects investor concerns regarding the potential impact on the company’s vaccine development pipeline, especially for the planned Phase 3 trial of the CIC vaccine, which is now likely delayed from the second half of 2024.
Despite the setback with the CIC vaccine, analysts at Jefferies remain confident in Novavax’s other vaccine offerings, particularly its COVID-19 vaccine. They indicated that there is no expected material impact on current vaccine sales resulting from the clinical hold. The firm also pointed out that the situation does not affect Novavax’s ongoing partnership with Sanofi, which continues to proceed unaffected.
While acknowledging the increased uncertainty surrounding the trial timeline, Jefferies emphasized that the potential upside could be substantial if Novavax successfully navigates the challenges posed by the clinical hold. The company’s robust pipeline and established presence in the vaccine market position it well for future growth, provided it can address the current issues effectively.
In summary, Novavax’s recent clinical hold on its flu combination vaccine program has led to a notable drop in stock value and heightened uncertainty about its trial timelines. Nevertheless, analysts maintain a positive outlook on the company's existing vaccine products, suggesting that the impact on sales and ongoing partnerships may be minimal. The coming weeks will be critical as Novavax works with the FDA to resolve the clinical hold and determine the path forward for its CIC vaccine program.
